ATB Capital Issues Pessimistic Forecast for Organigram (TSE:OGI) Stock Price

Organigram (TSE:OGI) had its price target lowered by ATB Capital from C$5.25 to C$3.50 in a research report released on Tuesday morning,BayStreet.CA reports.

Separately, Canaccord Genuity Group decreased their price objective on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research report on Monday, December 9th.

Organigram Trading Up 4.6 %

Shares of OGI opened at C$2.28 on Tuesday. The stock’s 50-day moving average is C$2.27 and its two-hundred day moving average is C$2.31. The stock has a market cap of C$247.54 million, a PE ratio of -0.91, a P/E/G ratio of 0.42 and a beta of 1.13. The company has a debt-to-equity ratio of 1.13, a current ratio of 6.95 and a quick ratio of 2.62. Organigram has a 12 month low of C$1.61 and a 12 month high of C$3.95.

Insider Buying and Selling at Organigram

In other news, Senior Officer Paolo De Luca sold 12,014 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of C$2.52, for a total transaction of C$30,275.28. 31.32% of the stock is currently owned by insiders.

About Organigram

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.